相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer
Kousaku Mimura et al.
CANCER SCIENCE (2018)
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer
Yohei Masugi et al.
GUT (2017)
Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway
Ting-ting Wang et al.
GUT (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1
Tingting Huang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1
Elizabeth A. McNiel et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
FGFR2 amplification in colorectal adenocarcinoma
Jamal H. Carter et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer
Kyu Sang Lee et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer
Shigehiro Koganemaru et al.
CANCER SCIENCE (2017)
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
Matthew W. Rosenbaum et al.
MODERN PATHOLOGY (2016)
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
Yaqi Li et al.
MOLECULAR CANCER (2016)
Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution
Yun-Hee Youm et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence
Christina Giannopoulou et al.
PHARMACOECONOMICS (2015)
Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction
Edward P. Carter et al.
TRENDS IN CELL BIOLOGY (2015)
Colorectal cancer
Ernst J. Kuipers et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis
Tinghong Ye et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
Minmin Song et al.
PLOS ONE (2013)
B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells
Sheng-Jia Shi et al.
PLOS ONE (2013)
FGFR2 gene amplification and clinicopathological features in gastric cancer
K. Matsumoto et al.
BRITISH JOURNAL OF CANCER (2012)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
Yoko Matsuda et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anticancer molecules targeting fibroblast growth factor receptors
Guang Liang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: A potential therapeutic target in colorectal cancer
Yoko Matsuda et al.
CANCER LETTERS (2011)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification
Anna A. Dudka et al.
CANCER RESEARCH (2010)
De-regulated FGF receptors as therapeutic targets in cancer
Victoria Knights et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Michael G. Gartside et al.
MOLECULAR CANCER RESEARCH (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
P. M. Pollock et al.
ONCOGENE (2007)
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
David J. Hunter et al.
NATURE GENETICS (2007)
PD-1 and its ligands in T-cell immunity
Mary E. Keir et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Somatic mutations of the protein kinase gene family in human lung cancer
H Davies et al.
CANCER RESEARCH (2005)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
